ArticleBMC infectious diseases2026
National real-life impact of prevention with nirsevimab on infants' RSV hospitalizations in Belgium.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Funding
Abstract
backgroundSince 2023, two preventive tools (monoclonal antibodies, nirsevimab, and preF maternal vaccine) were approved to protect infants against severe RSV infections. During winter 2024-2025, nirsevimab started to be administered in Belgium to infants < 6 months old encountering their first RSV season. We aim to evaluate on a national scale the impact of RSV prevention in the pediatric hospital setting.
methodThis survey pooled data from two surveillance systems: the prospective SARI (Severe Acute Respiratory Infection) surveillance (6 hospitals) and the retrospective RSVPed study (25 hospitals). Both used the same case definition and clinical questionnaire to record RSV hospitalizations in children < 5 years. Seasonal incidences and clinical data were compared between seasons 2023-2024 (pre-prevention) and 2024-2025 (first year of prevention).
resultsOur study covered 47% of all pediatric beds in Belgium. We demonstrated a reduction of 39% in pediatric RSV-related hospitalizations and of 57% in RSV-related admissions to intensive care units during 2024-2025 compared to 2023-2024. Incidences decline mainly concerned infants < 6 months, without changes in older age groups. Furthermore, savings in health care resources were observed through shorter length of stay and significantly less use of non-invasive ventilatory support and nutritional support among hospitalized cases in 2024-2025.
conclusionFollowing implementation of nirsevimab, a substantial reduction in RSV paediatric burden was observed in Belgium. However, efforts should be made to increase the uptake of preventive tools in our country to achieve better effectiveness. This study also highlights the major role of a national network to monitor efficacy of prevention over time. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.